PLEASANTON, CA -- (MARKET WIRE) -- October 11, 2006 -- Lipid Sciences, Inc. (NASDAQ: LIPD) announced that the Company's HDL Selective Delipidation technology platform was represented at presentations and workshops conducted at the New York ACE Meeting, a prestigious cardiovascular care conference held October 8-11. Presentations were made by: Dr. H. Bryan Brewer, Jr., Lipid Sciences' Vice Chairman, Chief Scientific Director, and member of the Lipid Sciences Board of Directors; and Dr. Ron Waksman, Director, Experimental Angioplasty and New Technologies, Cardiovascular Institute, and Associate Director, Division of Cardiology, Washington Hospital Center, and Principal Investigator for Lipid Sciences' "first in man" clinical trial for HDL Selective Delipidation.
